A plain-language review of what the retatrutide research actually shows — and what it still cannot promise.
Reviews Reta

Sources

Every retatrutide citation used on this site.

Peer-reviewed publications, Phase 1-3 trial results, and systematic reviews — each with DOI and PubMed link.

Primary sources

All citations are listed below. Numbers correspond to inline citations throughout the site. Every quantitative claim is traceable to one of these sources.

  1. Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. ↗
  2. Rosenstock J, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial. Lancet. 2023;402(10401):529-544. ↗
  3. Li W, Zhou Q, Cong Z, Yuan Q, Li W, Zhao F, Xu HE, Zhao LH, Yang D, Wang MW. Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide. Cell Discovery. 2024;10:77. ↗
  4. Urva S, Coskun T, Loh MT, Du Y, Thomas MK, Gurbuz S, Haupt A, Benson CT, Hernandez-Illas M, D'Alessio DA, Milicevic Z. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet. 2022;400:1869-1881. ↗
  5. Sanyal AJ, Kaplan LM, Frias JP, Brouwers B, Wu Q, Thomas MK, Harris C, Schloot NC, Du Y, Mather KJ, Haupt A, Hartman ML. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine. 2024;30:2037-2048. ↗
  6. Katsi V, Koutsopoulos G, Fragoulis C, Dimitriadis K, Tsioufis K. Retatrutide — A Game Changer in Obesity Pharmacotherapy. Biomolecules. 2025;15:796. ↗
  7. Bhat S, et al. Efficacy and safety of incretin co-agonists: Transformative advances in cardiometabolic healthcare. World Journal of Cardiology. 2025;17(8):107991. ↗
  8. Neumann J, et al. Acute Contractile Effects of Glucagon-like-Peptide-1 Receptor Agonists in the Human Heart. Pharmaceutics. 2026;18(4):447. ↗
  9. Pardali EC, et al. New Drugs on the Block: Dietary Management and Nutritional Considerations During the Use of Anti-Obesity Medication. Nutrients. 2026;18(6):962. ↗
  10. Alhazmi A, et al. Do no harm: managing nausea and vomiting in GLP-1 based obesity therapies. Frontiers in Endocrinology. 2026;17:1788698. ↗
  11. Cooper ME, et al. GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity. The Journal of Clinical Investigation. 2025;135(21):e194749. ↗
  12. Bajaj HS, et al. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. Lancet. 2026. DOI: 10.1016/S0140-6736(26)00967-0. ↗
  13. Abulehia A, et al. Comparative Efficacy and Safety of Glucagon Receptor Agonists on Metabolic Outcomes: A Network Meta-Analysis of Randomised Controlled Trials. Endocrinology, Diabetes & Metabolism. 2026. DOI: 10.1002/edm2.70187. ↗
  14. Chan ZH, et al. Incretin-Based Dual and Triple Agonists in Overweight or Obese Individuals: A Systematic Review and Meta-Analysis. Cardiology in Review. 2026. DOI: 10.1097/CRD.0000000000001209. ↗